Jorge Agustín Aguiar Santiago, Maria Acelia Marrero Miragaya, Dariel Adrian Figueroa Oliva, Andres Aguilar Juanes, Arletis Idavoy Corona, Seknia Martínez Fernández, Ivis Morán Bertot, Meilyn Rodríguez Hernández, Eduardo Canales López, Ingrid Hernández Esteves, José Angel Silva Girado, Regla Caridad Estrada Vázquez, Omar Gell Cuesta, Yssel Mendoza-Marí, Iris Valdés Prado, Chabeli Rodríguez Ibarra, Daniel Octavio Palenzuela Gardon, Eduardo Pentón Arias, Gerardo Guillén Nieto, Julio Cesar Aguilar Rubido
HeberNasvac, a therapeutic vaccine for chronic hepatitis B, is able to safely stimulate multiple Toll-like receptors, increasing antigen presentation in vitro and in a phase II clinical trial (Profira) in elderly volunteers who were household contacts of respiratory infection patients. Thus, a new indication as a postexposure prophylaxis or early therapy for respiratory infections has been proposed. In this study, we evaluated the expression of several interferon-stimulated genes (ISGs) after mucosal administration of HeberNasvac and compared this effect with the nasal delivery of interferon alpha 2b (Nasalferon)...
December 21, 2023: DNA and Cell Biology